Cost-effectiveness of the Adjuvanted Quadrivalent Influenza Vaccine for Older Adults in South Korea

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2024 May 7

PMID 38714332

Authors

Youngji Song

Eunha Shim

Affiliations

Soon will be listed here.

Abstract

South Korea's National Immunization Program administers the quadrivalent influenza vaccine (QIV) to manage seasonal influenza, with a particular focus on the elderly. After reviewing the safety and immune response triggered by the adjuvanted QIV (aQIV) in individuals aged 65 and older, the Ministry of Food and Drug Safety in Korea approved its use. However, the extensive impact of aQIV on public health is yet to be fully understood. This study assessed the cost-effectiveness of replacing QIV with aQIV in South Korean adults aged 65 years and older. A dynamic transmission model, calibrated with national influenza data, was applied to compare the influence of aQIV and QIV on older adults and the broader population throughout a single influenza season. This study considered both the direct and indirect effects of vaccination on the elderly. We derived the incremental cost-effectiveness ratios (ICERs) from quality-adjusted life-years (QALYs) and costs incurred, validated through a probabilistic sensitivity analysis with 5,000 simulations. Findings suggest that transitioning to aQIV from QIV in the elderly would be cost-effective, particularly if aQIV's efficacy reaches or exceeds 56.1%. With an ICER of $29,267/QALY, considerably lower than the $34,998/QALY willingness-to-pay threshold, aQIV presents as a cost-effective option. Thus, implementing aQIV with at least 56.1% efficacy is beneficial from both financial and public health perspectives in mitigating seasonal influenza in South Korea.

References

Marbaix S, Dauby N, Mould-Quevedo J . Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population. Expert Rev Vaccines. 2023; 22(1):608-619. DOI: 10.1080/14760584.2023.2229917. View

Angus D, Musthafa A, Clermont G, Griffin M, Dremsizov T, Pinsky M . Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001; 163(6):1389-94. DOI: 10.1164/ajrccm.163.6.2005123. View

Iuliano A, Roguski K, Chang H, Muscatello D, Palekar R, Tempia S . Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2017; 391(10127):1285-1300. PMC: 5935243. DOI: 10.1016/S0140-6736(17)33293-2. View

Longini Jr I, Halloran M, Nizam A, Yang Y . Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004; 159(7):623-33. DOI: 10.1093/aje/kwh092. View

Morse K, Cleveland K . Efficacy of the Adjuvanted Influenza Vaccine Compared With the High-Dose for Older People. Sr Care Pharm. 2023; 38(4):156-160. DOI: 10.4140/TCP.n.2023.156. View

Shin G, Kang D, Cheong H, Choi S . Cost-Effectiveness of Extending the National Influenza Vaccination Program in South Korea: Does Vaccination of Older Adults Provide Health Benefits to the Entire Population?. Vaccines (Basel). 2022; 10(6). PMC: 9228362. DOI: 10.3390/vaccines10060932. View

Choi M, Yun J, Song J, Ko K, Mould J, Cheong H . A Comparative Analysis of Influenza-Associated Disease Burden with Different Influenza Vaccination Strategies for the Elderly Population in South Korea. Vaccines (Basel). 2022; 10(9). PMC: 9503807. DOI: 10.3390/vaccines10091387. View

Hong T, Lee H, Kim N, Lee K, Kim Y, An J . Recent Increases in Influenza-Related Hospitalizations, Critical Care Resource Use, and In-Hospital Mortality: A 10-Year Population-Based Study in South Korea. J Clin Med. 2022; 11(16). PMC: 9410240. DOI: 10.3390/jcm11164911. View

10.

Ruiz-Aragon J, Marquez-Pelaez S, Gani R, Alvarez P, Guerrero-Luduena R . Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain. Vaccines (Basel). 2022; 10(2). PMC: 8879805. DOI: 10.3390/vaccines10020176. View

11.

Tregoning J, Russell R, Kinnear E . Adjuvanted influenza vaccines. Hum Vaccin Immunother. 2017; 14(3):550-564. PMC: 5861793. DOI: 10.1080/21645515.2017.1415684. View

12.

Wu D, Chaiyakunapruk N, Pratoomsoot C, Lee K, Chong H, Nelson R . Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics. Epidemiol Infect. 2018; 146(4):496-507. PMC: 9134563. DOI: 10.1017/S0950268818000158. View

13.

Seo J, Lim J . The impact of free vaccination policies under the Korean Influenza National Immunization Program: Trends in influenza vaccination rates in South Korea from 2010 to 2019. PLoS One. 2022; 17(1):e0262594. PMC: 8775253. DOI: 10.1371/journal.pone.0262594. View

14.

Yun J, Choi M, Shin G, Lim J, Noh J, Kim Y . Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea. PLoS One. 2019; 14(1):e0209643. PMC: 6347274. DOI: 10.1371/journal.pone.0209643. View

15.

Bolge S, Kariburyo F, Yuce H, Fleischhackl R . Predictors and Outcomes of Hospitalization for Influenza: Real-World Evidence from the United States Medicare Population. Infect Dis Ther. 2020; 10(1):213-228. PMC: 7954998. DOI: 10.1007/s40121-020-00354-x. View

16.

Macario A, Chow J, Dexter F . A Markov computer simulation model of the economics of neuromuscular blockade in patients with acute respiratory distress syndrome. BMC Med Inform Decis Mak. 2006; 6:15. PMC: 1431518. DOI: 10.1186/1472-6947-6-15. View

17.

Beyer W, McElhaney J, Smith D, Monto A, Nguyen-Van-Tam J, Osterhaus A . Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013; 31(50):6030-3. DOI: 10.1016/j.vaccine.2013.09.063. View

18.

Turner D, Wailoo A, Cooper N, Sutton A, Abrams K, Nicholson K . The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine. 2005; 24(7):1035-43. DOI: 10.1016/j.vaccine.2004.12.033. View

19.

Coleman B, Sanderson R, Haag M, McGovern I . Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021; 15(6):813-823. PMC: 8542957. DOI: 10.1111/irv.12871. View

20.

Galvani A, Reluga T, Chapman G . Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proc Natl Acad Sci U S A. 2007; 104(13):5692-7. PMC: 1838447. DOI: 10.1073/pnas.0606774104. View

21.

Calabro G, Boccalini S, Panatto D, Rizzo C, DI Pietro M, Abreha F . The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment. Int J Environ Res Public Health. 2022; 19(7). PMC: 8998177. DOI: 10.3390/ijerph19074166. View